Business Model & Revenue
TriSalus Life Sciences operates a hybrid business model combining a high-margin medical device franchise with an investigational therapeutic pipeline. The primary revenue engine is the commercial sale of its FDA-cleared TriNav and TriNav Advance infusion systems. These devices utilize proprietary Pressure-Enabled Drug Delivery (PEDD) technology to improve the delivery of therapeutics into solid tumors, particularly in the liver.
Revenue is highly recurring, driven by the consumable nature of the TriNav microcatheters used in embolization procedures. This "razor-and-blades" dynamic within hospital systems results in exceptional unit economics, evidenced by the company's 84.6% gross margin in 2025. TriSalus targets interventional radiologists, medical oncologists, and hospital value analysis committees to drive adoption.
Beyond devices, TriSalus is developing nelitolimod (SD-101), an investigational Toll-like receptor 9 (TLR9) agonist. The strategy is to utilize the PEDD technology to deliver nelitolimod directly into liver tumors, altering the immunosuppressive tumor microenvironment. If successful, this dual device-drug approach could transform the company from a medical device manufacturer into a fully integrated oncology therapeutics provider, unlocking exponentially larger addressable markets.
Financial Highlights
FY2025 Full-Year Results
| Metric | FY2025 | FY2024 | YoY |
|---|---|---|---|
| Total Revenue | $45.2M | $29.5M | +53.2% |
| Gross Profit | $38.2M | $25.4M | +50.3% |
| Gross Margin | 84.6% | 86.1% | -150bps |
| Net Loss | ($39.2M) | N/A | N/A |
Quarterly Progression — Revenue
| Quarter | Revenue |
|---|---|
| Q3 2025 | N/A |
| Q4 2025 | $13.2M |
| Q1 2026 | $8.9M |
2026 Guidance: Management reaffirmed full-year 2026 revenue guidance of $60 to $62 million, representing roughly 35% growth at the midpoint.
Competitive Landscape
TriSalus operates in a niche but highly contested space of interventional oncology and targeted drug delivery. The company differentiates itself through its proprietary PEDD mechanism, which specifically addresses the high interstitial fluid pressure within solid tumors that limits the efficacy of standard infusion methods.
Key competitors and alternative approaches include:
- Merit Medical Systems (MMSI): A massive player in disposable medical devices, including microcatheters and embolotherapy products. Merit possesses significant distribution scale, but TriSalus competes on the specialized clinical outcomes of its PEDD technology.
- Boston Scientific (BSX): Dominates portions of the interventional oncology market, particularly with its TheraSphere Y-90 glass microspheres. BSX's broad portfolio means TLSI must continually prove superior targeted delivery to win share.
- Sirtex Medical (Private): Known for SIR-Spheres (Y-90 resin microspheres) used in liver cancer. While they provide the therapeutic agent, TriSalus provides the delivery mechanism, making them sometimes complementary but always competing for hospital budget allocation.
- Terumo (TRUMY): A major Japanese medical device manufacturer with a strong presence in interventional systems and microcatheters.
TLSI's moats:
- Proprietary technology: The PEDD mechanism is patent-protected and clinically differentiated from standard end-hole microcatheters.
- Clinical evidence: Landmark studies, such as the real-world PEDD study of over 16,000 patients, demonstrate reduced post-procedure complications.
- High switching costs: Once interventional radiologists are trained on and comfortable with the TriNav system, hospital protocols create friction for switching to competitors.
Catalysts
- Commercial rollout of TriNav Advance. Following the September 22, 2026 FDA clearance, immediate launch and early adoption metrics in Q3/Q4 earnings will validate the market expansion thesis.
- Q3 2026 Earnings Report. Confirmation of the $60-$62 million full-year guidance and updates on the impact of TriNav Advance on the top line will likely drive institutional buying.
- Nelitolimod clinical data readouts. Any positive interim updates from the Phase 1 trial in uveal melanoma or hepatocellular carcinoma could provide significant upside optionality independent of device sales.
- Strategic partnerships. As a small-cap medtech, validation of the PEDD technology through co-development agreements with major pharma companies for targeted drug delivery would trigger a substantial re-rating.
Key Risks
- Clinical trial failure: The company is developing nelitolimod, an investigational immunotherapeutic in Phase 1 trials. Failure to demonstrate efficacy or safety could severely impact the stock's speculative premium.
- Cash burn and dilution: With a net loss of $39.2 million in 2025, TLSI may require additional capital raises before reaching cash flow positivity, which could dilute current shareholders.
- Commercial adoption execution: While FDA cleared, TriNav Advance must secure adoption from interventional radiologists and hospital value analysis committees. Slower-than-expected penetration would threaten 2026 revenue guidance.
- Reimbursement pressures: Changes in Medicare or private insurer reimbursement rates for liver embolization procedures could compress margins and limit hospital willingness to adopt premium PEDD devices.
- Competition: The oncology drug delivery market is highly competitive. Larger, better-capitalized medical device companies could develop alternative microcatheter technologies that bypass TriSalus's patents.
Our Thesis
TriSalus Life Sciences operates at the intersection of medical devices and oncology, a highly specialized niche with immense barriers to entry. The core value driver is its proprietary Pressure-Enabled Drug Delivery (PEDD) technology, which overcomes intra-tumoral pressure to deliver therapeutics directly into solid tumors. The FDA clearance of TriNav Advance is not just an incremental update; it allows physicians to access smaller, distal vessels, capturing a larger share of the liver embolization market and increasing revenue per procedure.
The valuation disconnect is stark. TLSI delivered 53% top-line growth in 2025 ($45.2 million) with an elite 84.6% gross margin. Management's 2026 revenue guidance of $60 to $62 million implies continued robust expansion of ≈35%. While the company is currently unprofitable (2025 net loss of $39.2 million), the high-margin recurring revenue from TriNav consumable sales creates tremendous operating leverage. Applying a conservative 7x multiple to the midpoint of 2026 revenue guidance yields a valuation of ≈$427 million, or roughly $8.30 per share. Factoring in the premium for the TriNav Advance clearance and the pipeline optionality of its investigational immunotherapeutic (nelitolimod), a 10x forward multiple is justified, supporting our $12.00 price target.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.